Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

269
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
269
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

The potential of key Alzheimer's plasma biomarkers to mimic tau PET MUBADA-based disease staging.

Alzheimer's research & therapy·2026
Same author

Concordance between domain-based neuropsychological profiles and clinical phenotypes in young-onset dementia.

The Clinical neuropsychologist·2026
Same author

Clinical drug development in amyotrophic lateral sclerosis: industry-reported challenges and opportunities.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same author

Amateur Soccer Heading and Acute Elevations in Blood-Based p-Tau217 and S100B.

JAMA neurology·2026
Same author

Top five Alzheimer Disease trial eligibility criteria favor men compared to women in a clinic-based cohort.

The journal of prevention of Alzheimer's disease·2026
Same author

Sex differences in documented clinical features of memory clinic patients: a natural language processing study.

Cerebral circulation - cognition and behavior·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Desarrollo de Fármacos

Lieza G Exalto1,2, Siti S Syaziyah3, Xiaotian T Fang1

  • 1Julius Clinical, Zeist, Netherlands.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Las mujeres tienen menos probabilidades de ser elegibles para la enfermedad de Alzheimer

Palabras clave:
Enfermedad de AlzheimerEnsayos clínicosCriterios de elegibilidadDesarrollo de fármacosParticipación de las mujeres

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Área de la Ciencia:

  • Neurología
  • Ensayos Clínicos
  • Investigación Médica

Sus antecedentes:

  • Los ensayos de fármacos para la enfermedad de Alzheimer (AD) a menudo carecen de participación femenina en relación con la población mundial de demencia.
  • Los interesados de la industria buscan ensayos inclusivos, centrándose en la participación y el reclutamiento.
  • Este estudio investiga cómo el diseño del ensayo, específicamente los criterios de elegibilidad, afecta las tasas de participación basadas en el sexo.

Objetivo del estudio:

  • Analizar la influencia de los criterios comunes de elegibilidad para ensayos clínicos de la enfermedad de Alzheimer en la proporción de hombres y mujeres elegibles para participar.
  • Identificar criterios específicos que afectan desproporcionadamente la elegibilidad de las mujeres en los ensayos de AD.

Principales métodos:

  • Se extrajeron los criterios de elegibilidad de 563 ensayos de fármacos de Fase II y III para AD registrados en clinicaltrials.gov.
  • Se anotaron manualmente 113 ensayos basándose en los 5 criterios de inclusión más comunes.
  • Se aplicaron estos criterios secuencialmente a una cohorte de hombres y mujeres diagnosticados con AD o Deterioro Cognitivo Leve (DCL) en el Centro de Alzheimer de Ámsterdam.

Principales resultados:

  • Los 5 criterios principales incluyeron: sin otro trastorno del sistema nervioso central (SNC), participación del cuidador, puntuación del Mini-Mental State Examination (MMSE) (24-30), sin contraindicaciones para los procedimientos del estudio y rango de edad (55-85).
  • La aplicación secuencial de estos criterios a 3835 pacientes (48% mujeres) disminuyó significativamente la elegibilidad para las mujeres.
  • La elegibilidad final fue del 31% para los hombres y del 16% para las mujeres, debido principalmente a puntuaciones más bajas en el MMSE y la falta de disponibilidad de cuidadores en las mujeres.

Conclusiones:

  • Los criterios de elegibilidad comúnmente utilizados en los ensayos clínicos de la enfermedad de Alzheimer resultan en tasas de elegibilidad más bajas para las mujeres en comparación con los hombres.
  • Las puntuaciones más bajas del MMSE en la presentación y la menor disponibilidad de cuidadores parecen ser factores clave que contribuyen a esta discrepancia.
  • Los diseños de los ensayos deben considerar estos factores para promover una inclusión más equitativa de las mujeres en los ensayos de fármacos para la AD.